Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emiko Sakaida

Showing results (31-40 of 171) with videos related to

Pageof 18
Sort By:
International Journal of Hematology|August 19, 2024
Efficacy and safety of recombinant porcine factor VIII in Japanese patients with acquired hemophilia AYoshinobu Seki, Yoshiyuki Ogawa, Takahide Kikuchi, et al.
International Journal of Hematology|February 18, 2014
Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation statusChika Kawajiri, Hiroaki Tanaka, Shinichiro Hashimoto, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|January 8, 2014
Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphomaKengo Fujimura, Hiroyuki Ebinuma, Isamu Fukamachi, et al.
Japanese Journal of Clinical Oncology|December 5, 2013
Incidence, risk factors and treatment outcomes of extravasation of cytotoxic agents in an outpatient chemotherapy clinicEmiko Sakaida, Ikuo Sekine, Shunichiro Iwasawa, et al.
International Journal of Hematology|September 11, 2021
Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trialHirohisa Nakamae, Masahide Yamamoto, Emiko Sakaida, et al.
Hematology (Amsterdam, Netherlands)|June 18, 2025
Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case seriesTomoki Suichi, Sonoko Misawa, Kazumoto Shibuya, et al.
American Journal of Hematology|August 6, 2011
Successful treatment with recombinant soluble thrombomodulin of two cases of sinusoidal obstructive syndrome/hepatic veno-occlusive disease after bone marrow transplantationChikako Ohwada, Masahiro Takeuchi, Takeharu Kawaguchi, et al.
International Journal of Hematology|August 13, 2022
Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 studyTakaaki Ono, Masayuki Hino, Itaru Matsumura, et al.
Japanese Journal of Clinical Oncology|October 4, 2017
CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapyYusuke Isshiki, Chikako Ohwada, Emiko Sakaida, et al.
International Journal of Hematology|April 13, 2020
Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemiaMasayuki Hino, Itaru Matsumura, Shin Fujisawa, et al.
Pageof 18

Showing results (31-40 of 171) with videos related to

Sort By:
Pageof 18
International Journal of Hematology|August 19, 2024
Efficacy and safety of recombinant porcine factor VIII in Japanese patients with acquired hemophilia AYoshinobu Seki, Yoshiyuki Ogawa, Takahide Kikuchi, et al.
International Journal of Hematology|February 18, 2014
Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation statusChika Kawajiri, Hiroaki Tanaka, Shinichiro Hashimoto, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|January 8, 2014
Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphomaKengo Fujimura, Hiroyuki Ebinuma, Isamu Fukamachi, et al.
Japanese Journal of Clinical Oncology|December 5, 2013
Incidence, risk factors and treatment outcomes of extravasation of cytotoxic agents in an outpatient chemotherapy clinicEmiko Sakaida, Ikuo Sekine, Shunichiro Iwasawa, et al.
International Journal of Hematology|September 11, 2021
Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trialHirohisa Nakamae, Masahide Yamamoto, Emiko Sakaida, et al.
Hematology (Amsterdam, Netherlands)|June 18, 2025
Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case seriesTomoki Suichi, Sonoko Misawa, Kazumoto Shibuya, et al.
American Journal of Hematology|August 6, 2011
Successful treatment with recombinant soluble thrombomodulin of two cases of sinusoidal obstructive syndrome/hepatic veno-occlusive disease after bone marrow transplantationChikako Ohwada, Masahiro Takeuchi, Takeharu Kawaguchi, et al.
International Journal of Hematology|August 13, 2022
Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 studyTakaaki Ono, Masayuki Hino, Itaru Matsumura, et al.
Japanese Journal of Clinical Oncology|October 4, 2017
CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapyYusuke Isshiki, Chikako Ohwada, Emiko Sakaida, et al.
International Journal of Hematology|April 13, 2020
Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemiaMasayuki Hino, Itaru Matsumura, Shin Fujisawa, et al.
Pageof 18